Key facts
- Hedera Dx’s last known valuation is $43.0M (Mar 2024).
- It has raised $36.8M; the latest was Early Stage VC ($16.9M) in May 2025.
- Notable investors include TA Ventures, Tesi, VSquared Ventures, GRIDS Capital, Blu Stone Management — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Hedera Dx
- ·The full record, as it builds
Funding rounds
No funding rounds for Hedera Dx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hedera Dx
Operator of a global cancer real-world data platform designed to enable molecular testing and AI-driven insights for improved cancer care outside the US. The company offers a unique integration of advanced genetic testing, liquid biopsies, and real-world data, enabling healthcare providers across international markets to deliver personalized treatment options, improving patient outcomes.
- Sector
- Healthcare
- HQ
- Epalinges, Switzerland
- Founded
- 2021
- Employees
- 21
- Website
- hederadx.com/
- Ownership
- Privately Held (backing)
Hedera Dx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hedera Dx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hedera Dx in its N-PORT filings yet. We sweep new filings monthly.